Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FGFR-2 antibody
- Development stage
- Unknown
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
An FGFR-2 antibody is a monoclonal or polyclonal antibody designed to target fibroblast growth factor receptor 2 (FGFR2), a receptor tyrosine kinase involved in cell proliferation, survival, and migration. Aberrant FGFR2 signaling, including overexpression, mutations, and gene fusions, is implicated in various cancers such as gastric, breast, ovarian, and prostate cancers, as well as cholangiocarcinoma. Therapeutic FGFR2 antibodies, such as bemarituzumab, act by blocking ligand binding and downstream signaling pathways (like MAPK and PI3K/Akt) or by mediating antibody-dependent cellular cytotoxicity (ADCC). Additionally, FGFR2 antibodies are widely used as research reagents for immunohistochemistry, western blotting, and flow cytometry to study FGFR2 expression in tissues and cell lines.
- Other names
- FGFR2 antibodyFGFR-2 antibodyFGFR 2 antibodyanti-FGFR-2 antibodyanti-FGFR2 antibodyanti-FGFR 2 antibodyanti-fibroblast growth factor receptor 2 antibodyfibroblast growth factor receptor 2 antibody
02
Targets
FGFR2 (Keratinocyte growth factor receptor)FcγRIIIa (Low affinity immunoglobulin gamma Fc region receptor III-A)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on FGFR-2 antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FGFR-2 antibody.